

David GÃ³mez-Almaguer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2614949/publications.pdf>

Version: 2024-02-01

275
papers

2,853
citations

185998

28
h-index

288905

40
g-index

289
all docs

289
docs citations

289
times ranked

3371
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes and survival predictors of Latin American older adults with acute myeloid leukemia: Data from a single center. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, 45, S43-S50.	0.1	1
2	Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 493-497.	0.5	3
3	Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort. <i>Clinical Rheumatology</i> , 2022, 41, 869-876.	1.0	5
4	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314.	0.6	8
5	Outpatient haploidentical hematopoietic stem cell transplant using post-transplant cyclophosphamide and incidence of hemorrhagic cystitis. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 163-168.	0.1	5
6	Desensitization to Brentuximab Vedotin after anaphylaxis in refractory Hodgkin's lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1264-1268.	0.5	2
7	Outpatient allogeneic hematopoietic stem-cell transplantation: a review. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	6
8	Hematopoietic stem cell transplantation for uncommon immune-mediated neurological disorders: A literature review. <i>Cytotherapy</i> , 2022, 24, 676-685.	0.3	4
9	Outpatient Based Autologous Hematopoietic Stem Cell Transplantation Is a Feasible Therapeutic Option for Patients with Chronic Inflammatory Demyelinating Polyneuropathy: The Mexican Experience. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S343.	0.6	0
10	Central Venous Access for Peripheral Stem Cell Collection in Autologous Donors: Safety-Related Outcomes of an Outpatient Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S254-S255.	0.6	0
11	Increasing Access to Transplantation in Mexico and Latin America through Telemedicine and a Partnership with be the Match. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S348-S349.	0.6	0
12	Cyclophosphamide Split in Two Blocks Apart Renders an Excellent Cardiac Safety Profile during Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis and Other Autoimmune Disorders. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S236-S237.	0.6	0
13	Socioeconomic Factors Related to Hematopoietic Stem Cell Transplantation for Autoimmune Disorders in North American and European Patients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S265-S266.	0.6	0
14	A Tale of Two Centers: Access to Private Care Improves Outcomes in Allogeneic Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S347-S348.	0.6	0
15	Switching to IV Melphalan with or without Low Dose Total Body Irradiation Reduces Primary Graft Failure Rates in Children with Malignancies When Busulfan Monitorization Is Unavailable. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S240-S242.	0.6	0
16	High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma. <i>Hematology</i> , 2022, 27, 449-455.	0.7	4
17	Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	3
18	Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America. <i>Hematology</i> , 2022, 27, 249-257.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkinâ€™s lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 505-508.	0.5	2
20	Outcomes of second hematopoietic stem cell transplantation using reducedâ€™intensity conditioning in an outpatient setting. <i>Hematological Oncology</i> , 2021, 39, 87-96.	0.8	1
21	Concordant acute myeloblastic leukemia in identical twins treated with allogeneic transplantation from a younger HLA-identical sibling following a single apheresis procedure. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH32.	0.7	1
22	Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 259.e1-259.e6.	0.6	11
23	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	0.6	34
24	Results of a completely outpatient autologous stem cell transplant program for lymphoma patients receiving reduced-intensity conditioning. <i>Leukemia and Lymphoma</i> , 2021, 62, 1619-1628.	0.6	5
25	Monthly variation in diagnosis of acute lymphoblastic leukemia and survival outcome in children and adults: 15-year trends at a single center. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, , .	0.1	0
26	Diagnoses, Outcomes, and Chronicity Predictors of Patients with Secondary Immune Thrombocytopenia: Ten-Year Data from a Hematology Referral Center. <i>Revista De Investigacion Clinica</i> , 2021, 73, 031-038.	0.2	0
27	Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 40-44.	1.2	5
28	The 1,000th Transplant for Multiple Sclerosis and Other Autoimmune Disorders at the HSCT-MÃ©xico Program: A Myriad of Experiences and Knowledge. <i>Frontiers in Neurology</i> , 2021, 12, 647425.	1.1	15
29	Increased blood transfusion after outpatient autologous transplantation with reduced intensity conditioning for hematological malignancies predicts worse outcomes. <i>Clinical Transplantation</i> , 2021, 35, e14247.	0.8	0
30	Acute Promyelocytic Leukemia: A Long-Term Retrospective Study in Mexico. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 53-63.	0.4	2
31	Contributions to the American Society of Hematology Meeting From Low- and Middle-Income Countries: An In-Depth Analysis and Call to Action. <i>JCO Global Oncology</i> , 2021, 7, 622-631.	0.8	1
32	Treating Acute Leukemia During the COVID-19 Pandemic in an Environment With Limited Resources: A Multicenter Experience in Four Latin American Countries. <i>JCO Global Oncology</i> , 2021, 7, 577-584.	0.8	13
33	Outpatient transplantation in the COVID-19 era: a single-center Latin American experience. <i>Bone Marrow Transplantation</i> , 2021, 56, 2287-2290.	1.3	3
34	The paradox of haematopoietic cell transplant in Latin America. <i>Bone Marrow Transplantation</i> , 2021, 56, 2382-2388.	1.3	4
35	A high transfusion burden following an ambulatory-allogeneic hematopoietic cell transplantation using reduced-intensity conditioning is associated with adverse outcomes. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 88, 102537.	0.6	0
36	The Influence of Nutritional Status at Diagnosis of Childhood B-Cell Acute Lymphoblastic Leukemia on Survival Rates: Data from a Hispanic Cohort. <i>Nutrition and Cancer</i> , 2021, , 1-7.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Treating thrombotic thrombocytopenic purpura without plasma exchange during the COVID-19 pandemic. A case report and a brief literature review. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103107.	0.5	1
38	Molecular and cellular markers for measurable residual disease in acute lymphoblastic leukemia. <i>Boletín Médico Del Hospital Infantil De México</i> , 2021, 78, 159-170.	0.2	2
39	Haploidentical hematopoietic cell transplantation for mycosis fungoides/ Sezary syndrome using reduced intensity conditioning after brentuximab therapy discontinuation: advantages of an outpatient program in the times of COVID-19. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 357-360.	0.1	1
40	Safety and feasibility of outpatient hematopoietic cell transplantation in pediatric patients during the COVID-19 pandemic: A single-center experience. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29252.	0.8	0
41	Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico. <i>Archives of Medical Research</i> , 2021, 52, 627-634.	1.5	2
42	Assessing the performance of a plateletpheresis unit at a tertiary-care academic medical center in Mexico: A 6-year experience. <i>Journal of Clinical Apheresis</i> , 2021, 36, 808-814.	0.7	0
43	Successful second outpatient autologous hematopoietic cell transplant for relapsed POEMS syndrome in a patient with coexisting HIV, HBV and syphilis infections during the COVID-19 pandemic. <i>Transplant Immunology</i> , 2021, 67, 101412.	0.6	2
44	Outpatient hematopoietic cell transplantation for older adults with hematologic malignancies: Results at an academic tertiary-care center. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	0
45	If We Have Seen Further, It is By Standing on The Shoulders of Giants. <i>Revista De Investigacion Clinica</i> , 2021, 73, 337-338.	0.2	0
46	Insights on chronic immune thrombocytopenia pathogenesis: A bench to bedside update. <i>Blood Reviews</i> , 2021, 49, 100827.	2.8	10
47	Performance of serum procalcitonin as a biochemical predictor of death in hematology patients with febrile neutropenia. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 90, 102586.	0.6	7
48	Perspectives in Diagnosis and Therapeutics in Hematology. <i>Revista De Investigacion Clinica</i> , 2021, 73, 306-309.	0.2	0
49	Poster: ALL-132: Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): PhALLCON Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S209.	0.2	0
50	Moral Distress: Its Manifestations in Healthy Donors during Peripheral Blood Hematopoietic Stem Cell Harvesting. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 853-858.	0.6	3
51	Pregnancy-associated aplastic anemia: a case-based review. <i>Expert Review of Hematology</i> , 2021, 14, 175-184.	1.0	0
52	OUP accepted manuscript. <i>American Journal of Clinical Pathology</i> , 2021, , .	0.4	0
53	An audit of platelet transfusion indications in acute leukaemia patients: six-year experience at an Academic Centre. <i>Blood Transfusion</i> , 2021, 19, 37-44.	0.3	1
54	Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study. <i>Blood</i> , 2021, 138, 606-606.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	1.3	46
56	Central Venous Access for Peripheral Stem Cell Collection in Autologous Donors: Safety within an Outpatient Transplantation Program. <i>Blood</i> , 2021, 138, 4850-4850.	0.6	0
57	Low-Dose Nivolumab Plus Brentuximab Vedotin As a Bridge to Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 4534-4534.	0.6	0
58	A Tale of Two Centers: Access to Private Care Improves Outcomes in Allogeneic Transplant Recipients. <i>Blood</i> , 2021, 138, 4890-4890.	0.6	0
59	Effective Treatment of Ph-Negative Acute Lymphoblastic Leukemia for Uninsured Hispanic Adolescents and Young Adults with a Low-Cost Outpatient Regimen. <i>Blood</i> , 2021, 138, 4102-4102.	0.6	2
60	Outpatient Based Autologous Hematopoietic Stem Cell Transplantation Is a Feasible Therapeutic Option for Patients with Chronic Inflammatory Demyelinating Polyneuropathy: The Mexican Experience. <i>Blood</i> , 2021, 138, 4897-4897.	0.6	1
61	Improvement Diagnosis and Treatment of Mantle Cell Lymphoma in a Middle-Income Country: A Time-Dependent Analysis in Mexico. <i>Blood</i> , 2021, 138, 3051-3051.	0.6	0
62	Romiplostim, Low-Dose Rituximab and High-Dose Dexamethasone Combination in Newly Diagnosed Immune Thrombocytopenia: Another "Total Therapy" Pilot Study. <i>Blood</i> , 2021, 138, 1014-1014.	0.6	4
63	Diagnostic concordance of pathological methods and reports of hematopathologists compared to local nonspecialized pathologists in the diagnosis of lymphoma in Mexico. <i>Hematology</i> , 2021, 26, 940-944.	0.7	1
64	Cyclosporine A for the Prevention of Ocular Graft versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Is Safe and Feasible. <i>Acta Haematologica</i> , 2020, 143, 425-431.	0.7	6
65	Palliative Care for Patients With Hematologic Malignancies in a Low-Middle Income Country: Prevalence of Symptoms and the Need for Improving Quality of Attention at the End of Life. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 600-605.	0.8	9
66	Childhood T-cell acute lymphoblastic leukemia in a single Latin American center: impact of improved treatment scheme and support therapy on survival. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 320-325.	0.1	3
67	Sexual Dimorphism in Children and Adolescents With Acute Lymphoblastic Leukemia: Influence on Incidence and Survival. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e293-e298.	0.3	0
68	Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries. <i>Hematology</i> , 2020, 25, 366-371.	0.7	4
69	Early changes in IL-21, IL-22, CCL2, and CCL4 serum cytokines after outpatient autologous transplantation for multiple sclerosis: A proof of concept study. <i>Clinical Transplantation</i> , 2020, 34, e14114.	0.8	10
70	Commentary on: First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2826-2827.	1.9	0
71	MÃ©lange intÃ©ressante: COVID-19, autologous transplants and multiple sclerosis. <i>Hematology</i> , 2020, 25, 320-320.	0.7	6
72	Pernicious anaemia can be treated effectively with a single high dose of cobalamin. <i>British Journal of Haematology</i> , 2020, 191, e97-e100.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center. <i>Annals of Hematology</i> , 2020, 99, 2513-2520.	0.8	10
74	Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. <i>Leukemia and Lymphoma</i> , 2020, 61, 3112-3119.	0.6	4
75	Building a hematopoietic cell transplantation outcomes registry in Mexico. <i>Bone Marrow Transplantation</i> , 2020, 55, 2279-2285.	1.3	1
76	A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 637-646.	0.2	3
77	Outpatient low toxic regimen with bortezomib in relapsed/refractory acute lymphoblastic leukemia in pediatric and AYA patients: Single-center Mexican experience. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28241.	0.8	6
78	The Road to Day 0: Barriers from HLA Typing to Infusion in the Era of Haploidentical Transplantation in Mexico. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S196-S197.	2.0	0
79	Mobilization kinetics of CD34+ hematopoietic stem cells stimulated by G-CSF and cyclophosphamide in patients with multiple sclerosis who receive an autotransplant. <i>Cytotherapy</i> , 2020, 22, 144-148.	0.3	5
80	Audit of red blood cell transfusion in patients with acute leukemia at a tertiary care university hospital. <i>Transfusion</i> , 2020, 60, 724-730.	0.8	2
81	Advances in the treatment of thrombotic thrombocytopenic purpura: repurposed drugs and novel agents. <i>Expert Review of Hematology</i> , 2020, 13, 461-470.	1.0	6
82	Self-Reported Changes in the Expanded Disability Status Scale (EDSS) Score in Persons with Multiple Sclerosis after Autologous Stem Cell Transplants: Experience with the "Mexican Method". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S20-S21.	2.0	0
83	Treating Acute Leukemia during the COVID-19 Pandemic: A Multicenter Latin American Registry. <i>Blood</i> , 2020, 136, 41-42.	0.6	1
84	The Leukoreductive Power of Vinblastine in Acute Myeloid Leukemia with Hyperleukocytosis: A Pilot Study. <i>Blood</i> , 2020, 136, 35-36.	0.6	1
85	Impact of HLA-DPB1 Matching on Clinical Outcomes after Haploidentical-Related Hematopoietic Stem Cell Transplantation. <i>Revista De Investigacion Clinica</i> , 2020, 72, 69-79.	0.2	1
86	Outpatient Transplantation during the COVID19 Pandemic: Stretching the Limits for Continuing Care. <i>Blood</i> , 2020, 136, 31-31.	0.6	0
87	Low Dose Rituximab Plus High Dose Dexamethasone As First-Line Treatment for Autoimmune Hemolytic Anemia. <i>Blood</i> , 2020, 136, 13-14.	0.6	1
88	Revisiting the complete blood count and clinical findings at diagnosis of childhood acute lymphoblastic leukemia: 10-year experience at a single center. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 57-61.	0.1	12
89	Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico. <i>Blood Research</i> , 2019, 54, 131-136.	0.5	11
90	Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study. <i>Transfusion</i> , 2019, 59, 3721-3726.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Consistency and reproducibility in the platelet-rich plasma preparation method: Mexican experience. <i>International Journal of Laboratory Hematology</i> , 2019, 41, e148-e151.	0.7	1
92	Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non-frozen grafts in persons with multiple sclerosis. <i>Clinical Transplantation</i> , 2019, 33, e13567.	0.8	7
93	Does Outcomes of HSCT Differ According to Patients' Socioeconomic Status? Real-World Data from an Outpatient-Based Center in Mexico. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S320-S321.	2.0	0
94	Assessing Patients' Knowledge and Attitudes Towards HSCT in an Outpatient-Based Transplant Center in Mexico. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S301.	2.0	0
95	Treatment of classical Hodgkin's lymphoma in children and adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1227-1234.	0.9	7
96	Frequency of HLA Alleles in a Mestizo Population: A Comparison between North-East and Central and South Mexico. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S211-S212.	2.0	0
97	Efficacy of three filgrastim-intended copies for hematopoietic stem cell mobilization in healthy adult and pediatric donors in Mexico. <i>Journal of Clinical Apheresis</i> , 2019, 34, 537-544.	0.7	5
98	HLA-Matched Related Versus Haploidentical Peripheral Blood Stem Cell Transplantation in Adults and Children. Real World Outcomes in Mexico. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S215.	2.0	1
99	Donor Lymphocyte Infusion from G-CSF-Primed, Unmanipulated Whole Blood Is Safe and Improves Chimerism in HLA-Matched and Haploidentical Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S171-S172.	2.0	2
100	Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. <i>Annals of Hematology</i> , 2019, 98, 941-949.	0.8	9
101	Outpatient Autotransplants for Persons with Multiple Sclerosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S319.	2.0	0
102	Treatment of diffuse large B-cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10-year results at a Latin American center. <i>Hematological Oncology</i> , 2019, 37, 226-229.	0.8	2
103	Cytokine Release Syndrome after Peripheral Blood T-Cell Replete Haploidentical Transplantation Is Not Prevented By Dexamethasone and Limits Its Full-Outpatient Conduction. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S136-S137.	2.0	0
104	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	2.5	37
105	Assessing the efficacy of an ambulatory peripheral blood hematopoietic stem cell transplant program using reduced intensity conditioning in a low-middle-income country. <i>Bone Marrow Transplantation</i> , 2019, 54, 828-838.	1.3	13
106	Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopenia. <i>British Journal of Haematology</i> , 2019, 184, 288-290.	1.2	21
107	Contributions to Global Hematology from Low and Middle-Income Countries: Insights from ASH 2018. <i>Blood</i> , 2019, 134, 2123-2123.	0.6	2
108	Moral Distress, Anxiety, and Others Physical Symptoms Related to Hematopoietic Stem Cell Donation. <i>Blood</i> , 2019, 134, 1967-1967.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Hematopoyesis extramedular pleural secundaria a anemia perniciosa grave. Medicina Clínica, 2019, 153, e7-e8.	0.3	0
110	Dengue durante el embarazo, menor incidencia de trombocitopenia que en la población general. Revista De Salud Publica, 2019, 21, 1-6.	0.0	1
111	A Multi-Institutional Validation of the Prognostic and Predictive Value of the Neutrophil-to-Lymphocyte Ratio in Patients with Diffuse Large B- Cell Lymphoma: A Study from the Latin American Working Group for Lymphomas (GELL). Blood, 2019, 134, 4121-4121.	0.6	0
112	Incorporating Reduced-Dose Plerixafor to a Preemptive Mobilization Algorithm Increases Access to Autologous Transplantation in a Limited-Resource Setting. Blood, 2019, 134, 4476-4476.	0.6	0
113	Unequal Outcomes in Transplant Eligible Patients with Multiple Myeloma in Latin America: Differences between Public and Private Centers. Blood, 2019, 134, 5497-5497.	0.6	0
114	Aspicular Bone Marrow Aspiration: A Common, but Not a Minor Problem. Blood, 2019, 134, 5841-5841.	0.6	0
115	Changing the Fate of Children with Acute Lymphoblastic Leukemia (ALL) in a Limited Resources Setting. Blood, 2019, 134, 5075-5075.	0.6	0
116	Tailored Prophylaxis in Mexican Pediatric Patients with Hemophilia a By Determining the Pharmacokinetics of Factor VIII. Blood, 2019, 134, 4922-4922.	0.6	0
117	The Road to Day 0: Identification of Barriers from HLA Typing to Transplantation in the Era of Haploidentical Grafts and Post-Transplant Cyclophosphamide. Blood, 2019, 134, 2057-2057.	0.6	0
118	Tocilizumab for Prophylaxis of Cytokine Release Syndrome after Outpatient-Based Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation. Blood, 2019, 134, 5624-5624.	0.6	1
119	Assessment of Different Biological Variables (Serum Albumin, β_2 -Microglobulin, Lymphocyte/Monocyte) Tj ETQq1 1 0.784314 rgBT / Ov Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival. Blood, 2019, 134, 1613-1613.	0.6	0
120	Impact of Obesity on Lumbar Puncture Outcomes in Adults with Acute Lymphoblastic Leukemia and Lymphoma: Experience at an Academic Reference Center. International Journal of Hematology-Oncology and Stem Cell Research, 2019, 13, 146-152.	0.3	2
121	Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. Cancer, 2018, 124, 1946-1953.	2.0	19
122	Outcomes of Adolescents and Young Adults With Acute Myeloid Leukemia Treated in a Single Latin American Center. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 286-292.	0.2	19
123	Iron deficiency anemia referral to the hematologist. Real-world data from Mexico: the need for targeted teaching in primary care. Hematology, 2018, 23, 658-663.	0.7	6
124	Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transplantation, 2018, 53, 457-460.	1.3	28
125	Relapse of childhood acute lymphoblastic leukemia and outcomes at a reference center in Latin America: organomegaly at diagnosis is a significant clinical predictor. Hematology, 2018, 23, 1-9.	0.7	22
126	The effect of intra-articular injection of autologous bone marrow stem cells on pain and knee function in patients with osteoarthritis. International Journal of Rheumatic Diseases, 2018, 21, 140-147.	0.9	65

#	ARTICLE	IF	CITATIONS
127	Danazol as First-Line Therapy for Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e109-e113.	0.2	16
128	Evans syndrome: clinical perspectives, biological insights and treatment modalities. <i>Journal of Blood Medicine</i> , 2018, Volume 9, 171-184.	0.7	54
129	Eltrombopag-based combination treatment for immune thrombocytopenia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 309-317.	1.1	15
130	Clinical presentation in thrombotic thrombocytopenic purpura: Real-world data from two Mexican institutions. <i>Journal of Clinical Apheresis</i> , 2018, 33, 645-653.	0.7	9
131	Platelet Survival in Hematology Patients Assessed by the Corrected Count Increment and Other Formulas. <i>American Journal of Clinical Pathology</i> , 2018, 150, 267-272.	0.4	9
132	Contributions of a regional approach to document hematologic disease in Mexico: a 10-year experience in an open population. <i>Hematology</i> , 2018, 23, 803-809.	0.7	8
133	Outpatient-Based Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide is Feasible. Experience in a Single Latin-American Center. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S407-S408.	2.0	0
134	Outpatient Autotransplants for Persons with Multiple Sclerosis. <i>Blood</i> , 2018, 132, 4618-4618.	0.6	1
135	Cytokine Release Syndrome after Peripheral Blood T-Cell Replete Haploidentical Transplantation Is Not Prevented By Dexamethasone and Limits Its Full-Outpatient Conduction. <i>Blood</i> , 2018, 132, 3355-3355.	0.6	0
136	Supplementation with Selenium As Prevention for the Development of Mucositis in Patients Undergoing HSCT. Results of a Pilot Study. <i>Blood</i> , 2018, 132, 3363-3363.	0.6	0
137	"Ultrasensitive Reactive C-Protein As an Affordable Biomarker of Quantitative Expression of the BCR-ABL Transcript in Chronic Myeloid Leukemia. an Exploratory Study.". <i>Blood</i> , 2018, 132, 5450-5450.	0.6	0
138	Donor Lymphocyte Infusion from G-CSF-Primed, Unmanipulated Whole Blood Is Safe and Improves Chimerism in HLA-Matched and Haploidentical Transplantation. <i>Blood</i> , 2018, 132, 4602-4602.	0.6	0
139	International Prognostic Indexes (IPI, RIPI, NCCN-IPI) for Predicting Overall Survival in Diffuse Large B-Cell Lymphoma Can be Improved By Adding Serum Albumin As Another Predictive Factor. Retrospective Study of the Mexican Study Group in Lymphoma from a Database of 855 Patients. <i>Blood</i> , 2018, 132, 1707-1707.	0.6	0
140	Newly Diagnosed Pernicious Anemia Can be Treated with a Single Megadose of Cobalamin. Results of a Pilot Trial. <i>Blood</i> , 2018, 132, 1043-1043.	0.6	0
141	TNF- α increases in the CSF of children with acute lymphoblastic leukemia before CNS relapse. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 63, 27-31.	0.6	5
142	Do immunoglobulin G and immunoglobulin E anti-I-asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 202-209.	0.7	9
143	Hospitalization rate and costs in acute lymphoblastic leukemia of childhood in a low-income group: Financial impact in Northeast Mexico. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26673.	0.8	9
144	Measurements of Catheter, Venous, and Capillary Cyclosporine A Blood Are Comparable and Useful in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Acta Haematologica</i> , 2017, 137, 113-116.	0.7	1

#	ARTICLE	IF	CITATIONS
145	Plateletpheresis efficiency and mathematical correction of software-derived platelet yield prediction: A linear regression and ROC modeling approach. <i>Journal of Clinical Apheresis</i> , 2017, 32, 329-334.	0.7	4
146	Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26396.	0.8	22
147	High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 325-330.	0.7	16
148	The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study. <i>Annals of Hematology</i> , 2017, 96, 2015-2024.	0.8	5
149	Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. <i>Expert Review of Hematology</i> , 2017, 10, 809-819.	1.0	7
150	Economic Challenges in Hematopoietic Cell Transplantation: How Will New and Established Programs Face the Growing Costs?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1815-1816.	2.0	6
151	Age Acts as an Adverse Independent Variable for Survival in Acute Lymphoblastic Leukemia: Data From a Cohort in Northeast Mexico. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 590-594.	0.2	8
152	Altered CSF cytokine network in amyotrophic lateral sclerosis patients: A pathway-based statistical analysis. <i>Cytokine</i> , 2017, 90, 1-5.	1.4	16
153	Observational study of multiple myeloma in Latin America. <i>Annals of Hematology</i> , 2017, 96, 65-72.	0.8	29
154	Survival Rates of Adults With Acute Lymphoblastic Leukemia in a Low-Income Population: A Decade of Experience at a Single Institution in Mexico. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 60-68.	0.2	15
155	Comparative analysis of iron status and other hematological parameters in preeclampsia. <i>Hematology</i> , 2017, 22, 36-40.	0.7	14
156	Acute Leukemia Characteristics are Different Around the World: the Mexican Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 46-51.	0.2	28
157	Myelodysplasia and acute myeloid leukemia fifteen years after high-dose cyclophosphamide in a child with severe aplastic anemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 57-59.	0.7	1
158	Prevalence and Clinical Significance of FLT3 Mutation Status in Acute Myeloid Leukemia Patients: A Multicenter Study. <i>Archives of Medical Research</i> , 2016, 47, 172-179.	1.5	12
159	Results of Treating Childhood Acute Lymphoblastic Leukemia in a Low-middle Income Country: 10-Year Experience in Northeast Mexico. <i>Archives of Medical Research</i> , 2016, 47, 668-676.	1.5	17
160	Importance of Nutrition in the Treatment of Leukemia in Children and Adolescents. <i>Archives of Medical Research</i> , 2016, 47, 585-592.	1.5	32
161	The treatment of CML at an environment with limited resources. <i>Hematology</i> , 2016, 21, 576-582.	0.7	11
162	Flow cytometry data analysis of CD34+/CD133+ stem cells in bone marrow and peripheral blood and T, B, and NK cells after hematopoietic grafting. <i>Data in Brief</i> , 2016, 7, 1151-1155.	0.5	2

#	ARTICLE	IF	CITATIONS
163	Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure. <i>Hematology</i> , 2016, 21, 411-414.	0.7	6
164	A clinical challenge: Treatment of acute myeloid leukemia in a Jehovah's Witness. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 358-360.	0.7	2
165	Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2033-2037.	0.8	17
166	Hairy cell leukemia, an uncommon B-cell lymphoid neoplasia. <i>Medicina Universitaria</i> , 2016, 18, 34-41.	0.1	1
167	More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. <i>Hematology</i> , 2016, 21, 311-316.	0.7	27
168	Long-Term Insulin Independence in Type 1 Diabetes Mellitus Using a Simplified Autologous Stem Cell Transplant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2141-2148.	1.8	24
169	Assessment of immune reconstitution status in recipients of a successful hematopoietic stem cell transplant from peripheral blood after reduced intensity conditioning. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 58, 52-56.	0.6	6
170	Impact of outpatient non-myeloablative haematopoietic stem cell transplantation in quality of life vs. conventional therapy. <i>Psychology, Health and Medicine</i> , 2016, 21, 10-19.	1.3	8
171	Eltrombopag, Low-Dose Rituximab, and High-Dose Dexamethasone Combination for Patients with Newly Diagnosed Immune Thrombocytopenia: A Pilot "Total Therapy" Study. <i>Blood</i> , 2016, 128, 1369-1369.	0.6	2
172	Results from Hemato-Oncology Latin America Observational Registry (HOLA) Providing Real World Outcomes for the Treatment of Patients with CLL. <i>Blood</i> , 2016, 128, 5578-5578.	0.6	4
173	Ocular Graft-Versus Host Disease Prevention with Topical Cyclosporine in Non-Myeloablative Allogeneic Stem Cell Transplant. <i>Blood</i> , 2016, 128, 4569-4569.	0.6	0
174	Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia. <i>Cancer Biomarkers</i> , 2015, 15, 299-310.	0.8	39
175	Effective collection of peripheral blood stem cells in children weighing 20 kilogram or less in a single large-volume apheresis procedure. <i>Journal of Clinical Apheresis</i> , 2015, 30, 281-287.	0.7	22
176	Identification of Differentially Expressed Genes Associated with Prognosis of B Acute Lymphoblastic Leukemia. <i>Disease Markers</i> , 2015, 2015, 1-11.	0.6	16
177	Safety and Cost-Effectiveness of a Simplified Method for Lumbar Puncture in Patients with Hematologic Malignancies. <i>Acta Haematologica</i> , 2015, 133, 168-171.	0.7	5
178	Experience with Evans syndrome in an academic referral center. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 230-235.	0.7	15
179	Matched sibling donors versus alternative donors in allogeneic hematopoietic stem cell transplantation for pediatric severe aplastic anemia in Mexico. <i>Hematology</i> , 2015, 20, 449-454.	0.7	5
180	Increased Bacterial Infections after Transfusion of Leukoreduced Non-Irradiated Blood Products in Recipients of Allogeneic Stem Cell Transplants after Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 526-530.	2.0	7

#	ARTICLE	IF	CITATIONS
181	Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience. <i>Leukemia and Lymphoma</i> , 2015, 56, 2524-2528.	0.6	3
182	Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico. <i>Oncologist</i> , 2015, 20, 386-392.	1.9	48
183	Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma. <i>Archives of Medical Research</i> , 2015, 46, 454-461.	1.5	14
184	Cultural factors related to adherence to imatinib in CML: A Mexican perspective. <i>Hematology</i> , 2015, 20, 72-76.	0.7	7
185	Haploidentical Bone Marrow Transplantation in 2015 and Beyond. <i>Current Oncology Reports</i> , 2015, 17, 57.	1.8	10
186	Health-Related Quality of Life in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation Employing the Mexican Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S179.	2.0	0
187	Evaluation of hemoglobin performance in the assessment of iron stores in feto-maternal pairs in a high-risk population: receiver operating characteristic curve analysis. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015, 37, 178-183.	0.7	7
188	Low Dose Rituximab and Plasma Exchange As Frontline Therapy for Patients with Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2015, 126, 2257-2257.	0.6	0
189	Outpatient Haploidentical Peripheral Blood Stem-Cell Transplantation with Post-Transplant Cyclophosphamide in Children and Adolescents. <i>Blood</i> , 2015, 126, 4389-4389.	0.6	0
190	Cyclophosphamide, Gemcitabine, Vinorelbine and Prednisone (CGEV) As Salvage Therapy for Relapsed or Refractory Hodgkin's Lymphoma before Hematopoietic Stem Cell Transplantation: A Single Center Experience. <i>Blood</i> , 2015, 126, 1523-1523.	0.6	0
191	Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts. <i>Blood</i> , 2015, 126, 4492-4492.	0.6	0
192	Health-Related Quality of Life in leukemia Survivors of Allogeneic Hematopoietic Stem Cell Transplantation Employing the Mexican Reduced-Intensity Conditioning. <i>Revista De Investigacion Clinica</i> , 2015, 67, 109-16.	0.2	1
193	Feasibility of an outpatient HLA haploidentical stem cell transplantation program in children using a reduced-intensity conditioning regimen and CD34 ⁺ CD19 ⁻ depletion. <i>Hematology</i> , 2014, 19, 10-17.	0.7	4
194	Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO incompatible patients: are survival and graft-versus-host disease different?. <i>Transfusion</i> , 2014, 54, 1269-1277.	0.8	15
195	Characteristics and Clinical Evolution of Patients with Acute Myeloblastic Leukemia in Northeast Mexico: An Eight-Year Experience at a University Hospital. <i>Acta Haematologica</i> , 2014, 132, 144-151.	0.7	13
196	Chemotherapy Alone or HSCT After Reduced-Intensity Conditioning for Patients with Malignant Hematologic Diseases Are Not Associated to Metabolic Syndrome: A Cross-Sectional Observational Study. <i>Nutrition and Cancer</i> , 2014, 66, 924-929.	0.9	0
197	Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial. <i>Cytotherapy</i> , 2014, 16, 810-820.	0.3	43
198	Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. <i>Blood</i> , 2014, 123, 3906-3908.	0.6	66

#	ARTICLE	IF	CITATIONS
199	Unmanipulated Peripheral Blood Stem Cells Can be Safely Used to Allograft Patients with Severe Aplastic Anemia; The Impact of ATG in Latin American Experience. <i>Blood</i> , 2014, 124, 1255-1255.	0.6	0
200	Autologous Hematopoietic Stem Cell Transplant in Type 1 Diabetes Mellitus in a Nonmyeloablative and Outpatient Setting. <i>Blood</i> , 2014, 124, 1191-1191.	0.6	2
201	Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients. <i>Diabetology and Metabolic Syndrome</i> , 2013, 5, 18.	1.2	57
202	Current Approaches for the Treatment of Autoimmune Hemolytic Anemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 385-395.	1.0	23
203	Obesity is associated with higher overall survival in patients undergoing an outpatient reduced-intensity conditioning hematopoietic stem cell transplant. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 61-65.	0.6	26
204	High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. <i>European Journal of Haematology</i> , 2013, 90, 494-500.	1.1	46
205	Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease. <i>Journal of Clinical Apheresis</i> , 2013, 28, 349-355.	0.7	29
206	Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia. <i>Hematology</i> , 2013, 18, 224-229.	0.7	3
207	More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2013, 129, 18-19.	0.7	5
208	Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. <i>Blood</i> , 2013, 121, 1935-1943.	0.6	96
209	Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP. <i>Blood</i> , 2013, 122, 3544-3544.	0.6	1
210	Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study. <i>Blood</i> , 2013, 122, 4034-4034.	0.6	1
211	Prevalence Of FLT3 Mutations In Acute Myeloid Leukemia: A Multicenter Latin America Study. <i>Blood</i> , 2013, 122, 4979-4979.	0.6	8
212	Subsequent Malignant Neoplasms After Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and Outpatient Conduction. <i>Blood</i> , 2013, 122, 5502-5502.	0.6	2
213	Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. <i>Haematologica</i> , 2012, 97, 717-722.	1.7	22
214	Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP). <i>Hematology</i> , 2012, 17, s25-s27.	0.7	5
215	Skin Manifestations Associated with Chemotherapy in Children with Hematologic Malignancies. <i>Pediatric Dermatology</i> , 2012, 29, 264-269.	0.5	5
216	Acute maternal cytomegalovirus infection is associated with significantly decreased numbers of CD34+ cells in umbilical cord blood. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 166-169.	0.6	4

#	ARTICLE	IF	CITATIONS
217	Acute lymphoblastic leukemia of childhood presenting as aplastic anemia: report of two cases. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 165-167.	0.7	15
218	Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. <i>American Journal of Hematology</i> , 2012, 87, 941-941.	2.0	6
219	Antibodies in the Treatment of Aplastic Anemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 99-106.	1.0	12
220	Use of complementary and alternative medicine by patients with hematological diseases: experience at a university hospital in northeast Mexico. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 103-108.	0.7	4
221	Low-Dose Rituximab and High-Dose Dexamethasone As Front-Line Therapy in Adult Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2012, 120, 3332-3332.	0.6	0
222	Reduced-Intensity Allografting in Childhood Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 439-440.	2.0	2
223	Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. <i>European Journal of Haematology</i> , 2011, 87, 521-530.	1.1	13
224	Danazol as first-line therapy for aplastic anemia. <i>Annals of Hematology</i> , 2011, 90, 523-527.	0.8	59
225	Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia?. <i>Pediatric Blood and Cancer</i> , 2011, 57, 217-223.	0.8	16
226	Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters. <i>American Journal of Clinical Pathology</i> , 2011, 136, 721-726.	0.4	30
227	Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. <i>Blood</i> , 2010, 116, 4783-4785.	0.6	67
228	Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. <i>Annals of Hematology</i> , 2010, 89, 299-303.	0.8	25
229	Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. <i>Annals of Hematology</i> , 2010, 89, 1045-1052.	0.8	10
230	Outpatient reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukaemia in children. <i>British Journal of Haematology</i> , 2010, 151, 200-202.	1.2	0
231	Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. <i>British Journal of Haematology</i> , 2009, 144, 794-795.	1.2	44
232	Dimethyl Sulfoxide-Induced Toxicity in Cord Blood Stem Cell Transplantation: Report of Three Cases and Review of the Literature. <i>Acta Haematologica</i> , 2009, 122, 1-5.	0.7	69
233	Random serum methotrexate determinations for assessing compliance with maintenance therapy for childhood acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 1843-1847.	0.6	11
234	Alemtuzumab and Rituximab in the treatment of refractory autoimmune Cytopenias.. <i>Blood</i> , 2009, 114, 4458-4458.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Improving the Treatment Outcome of Acute Promyelocytic Leukemia in Developing Countries through International Cooperative Network. Report On the International Consortium On Acute Promyelocytic Leukemia Study Group.. Blood, 2009, 114, 6-6.	0.6	11
236	A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting. Blood Transfusion, 2009, 7, 127-31.	0.3	4
237	Assessment of nutritional status in children with acute lymphoblastic leukemia in Northern MÃ©xico: A 5-year experience. Pediatric Blood and Cancer, 2008, 50, 506-508.	0.8	26
238	Subcutaneous Alemtuzumab May Be Useful in the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.. Blood, 2007, 110, 2983-2983.	0.6	50
239	Transient mixed chimerism after stem cell transplantation can induce durable molecular complete remissions in chronic myelogenous leukemia. Leukemia and Lymphoma, 2006, 47, 2590-2592.	0.6	2
240	Nephrotic syndrome after non-myeloablative stem cell transplantation. British Journal of Haematology, 2006, 132, 801-801.	1.2	6
241	Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen. European Journal of Haematology, 2006, 77, 341-344.	1.1	2
242	Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican experience. American Journal of Hematology, 2006, 81, 157-161.	2.0	42
243	Alemtuzumab in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease.. Blood, 2006, 108, 5294-5294.	0.6	0
244	Second allogeneic peripheral blood stem cell transplants with reduced-intensity conditioning. Revista De Investigacion Clinica, 2006, 58, 34-8.	0.2	6
245	Extramedullary Leukemic Relapses following Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning. International Journal of Hematology, 2005, 82, 262-265.	0.7	14
246	Sub-Optimal Fetal Iron Acquisition under a Maternal Environment. Archives of Medical Research, 2005, 36, 598-602.	1.5	42
247	Haematopoietic stem cell transplantation to treat aplastic anaemia. Expert Opinion on Biological Therapy, 2005, 5, 617-626.	1.4	12
248	Platelet refractoriness to classical agonists in a child with essential thrombocythemia. Platelets, 2005, 16, 61-62.	1.1	2
249	Platelet aggregation in children with acute lymphoblastic leukemia during induction of remission therapy. Archives of Medical Research, 2004, 35, 141-144.	1.5	9
250	Breaking dogmata to help patients: non-myeloablative haematopoietic stem cell transplantation. Expert Opinion on Biological Therapy, 2004, 4, 1693-1699.	1.4	15
251	Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning in Patients with Acute Myelogenous Leukemia Eligible for Conventional Allografting: A Prospective Study. Leukemia and Lymphoma, 2004, 45, 1191-1195.	0.6	28
252	The Mexican Approach to Conduct Nonmyeloablative Stem Cell Transplantation Should Not Be Overlooked. International Journal of Hematology, 2003, 77, 526-527.	0.7	8

#	ARTICLE	IF	CITATIONS
253	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 157-161.	2.0	51
254	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 157-161.	2.0	41
255	The complex nature of the prothrombotic state in acute lymphoblastic leukemia of childhood. <i>Haematologica</i> , 2003, 88, ELT25.	1.7	4
256	Iron Stores in Low-Income Pregnant Mexican Women at Term. <i>Archives of Medical Research</i> , 2002, 33, 81-84.	1.5	9
257	The simplification of the SCT procedures in developing countries has resulted in cost-lowering and availability to more patients. <i>International Journal of Hematology</i> , 2002, 76, 380-382.	0.7	37
258	Platelet aggregation is stimulated by L-asparaginase in children with acute lymphoblastic leukemia and normal individuals. <i>Haematologica</i> , 2002, 87, 891-2.	1.7	6
259	Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. <i>Haematologica</i> , 2002, 87, 894-6.	1.7	22
260	Features of the Engraftment of Allogeneic Hematopoietic Stem Cells Using Reduced-Intensity Conditioning Regimens. <i>Leukemia and Lymphoma</i> , 2001, 42, 145-150.	0.6	13
261	High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. <i>American Journal of Hematology</i> , 2001, 66, 71-71.	2.0	28
262	Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. <i>American Journal of Hematology</i> , 2001, 66, 241-244.	2.0	70
263	Immunoreactivity of Common Red Blood Cell Antigens in Cytoskeleton-Free Red Blood Cell Microvesicles. <i>Archives of Medical Research</i> , 2000, 31, 169-171.	1.5	3
264	Bone Marrow Transplantation in a Child with Hemophagocytic Lymphohistiocytosis Using a Less Toxic Conditioning Regimen. <i>Archives of Medical Research</i> , 1999, 30, 338-340.	1.5	5
265	Alltrans-retinoic acid decreases early mortality in patients with promyelocytic leukemia and can be given entirely on an outpatient basis. , 1999, 62, 139-143.		4
266	Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. , 1998, 78, 52-55.		30
267	Nutritional status and socio-economic conditions as prognostic factors in the outcome of therapy in childhood acute lymphoblastic leukemia. <i>International Journal of Cancer</i> , 1998, 78, 52-55.	2.3	4
268	Chemotherapy Alone May Be An Efficient Alternative in the Treatment of Early Stage Hodgkin's Disease if Optimal Radiotherapy is Not Available. <i>Leukemia and Lymphoma</i> , 1997, 27, 179-183.	0.6	3
269	Hairy cell leukemia is infrequent in MÃ©xico and has a geographic distribution. , 1996, 52, 316-318.		15
270	Dexamethasone in the treatment of meningeal leukemia. <i>American Journal of Hematology</i> , 1995, 49, 353-354.	2.0	8

#	ARTICLE	IF	CITATIONS
271	Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. <i>European Journal of Haematology</i> , 1995, 54, 18-20.	1.1	28
272	Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. <i>British Journal of Haematology</i> , 1992, 82, 671-675.	1.2	22
273	Vasculitis in hairy cell leukemia: Rapid response to interferon alpha. <i>American Journal of Hematology</i> , 1989, 30, 261-262.	2.0	6
274	Acyclovir in the treatment of aplastic anemia. <i>American Journal of Hematology</i> , 1988, 29, 172-173.	2.0	4
275	Alternatives for managing patients with newly diagnosed immune thrombocytopenia: a narrative review. <i>Expert Review of Hematology</i> , 0, , 1-10.	1.0	1